Learn How an mRNA-Encoded Antibody Platform Could Accelerate Therapies to Clinic
Therapeutic antibody manufacturing requires expensive and complex production that keeps treatment costs high, and encoding antibodies with mRNA has the potential to circumvent many traditional antibody manufacturing challenges. With new data illustrating preclinical feasibility, the approach has recently matured to a viable therapeutic option.
This webinar will outline an mRNA-LNP based platform and roadmap to encode and deliver therapeutic antibodies in vivo within a patient, using the standard-of-care anti-HER2 antibody Trastuzumab as a case study. It will show that mRNA-encoded antibodies are comparable to infused recombinant equivalents in terms of reaching appropriate therapeutic levels, as well as demonstrate in vitro and in vivo efficacy validation.
This proof-to-concept data aims to establish that mRNA-encoded therapeutic antibodies can provide an effective, alternate approach for solid tumor immunotherapy, unlocking a strategy to democratize and enhance patient access to biologics. The webinar reviews the process of designing and delivering mRNA-encoded antibodies, as well as the benefits and challenges of the new approach.
Key Learning Objectives:
- Discover the possibilities of mRNA-encoded antibodies compared to traditional antibody manufacturing
- Learn how mRNA-encoded antibodies are designed and delivered
- Understand the safety and efficacy validation of mRNA-encoded antibodies
- Learn how mRNA encoding might facilitate your next antibody discovery and development project
About the Presenters
Sourav Mukherjee, PhD
Vice President, Business Development, Vernal Biosciences
Dan Rocca, PhD
Senior Research Leader, Advanced Modalities, Charles River